Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development

Barr, Alastair J. (2010) Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Medicinal Chemistry, 2 (10). pp. 1563-1576. ISSN 1756-8919

Full text not available from this repository.
Official URL: http://dx.doi.org/10.4155/fmc.10.241

Abstract

Several 'classical' protein tyrosine phosphatases are attractive therapeutic targets, including PTP1B for obesity and Type II diabetes; SHP2 for cancer and Lyp for rheumatoid arthritis. Progress has been made in identifying a broad range of chemically distinct inhibitors; however, developing selective and cell-permeable clinically useful compounds has proved challenging. Here the ongoing challenges and recent significant advances in the field are reviewed. Key novel compounds are highlighted and a perspective on the future of phosphatase inhibitor development is presented.

Item Type: Article
Subjects: University of Westminster > Science and Technology > Life Sciences, School of (No longer in use)
Depositing User: Rachel Wheelhouse
Date Deposited: 20 Jul 2012 14:59
Last Modified: 11 Jun 2013 10:08
URI: http://westminsterresearch.wmin.ac.uk/id/eprint/10879

Actions (login required)

Edit Item (Repository staff only) Edit Item (Repository staff only)